Efficacy of Once-Weekly Exenatide Versus Once or Twice Daily Insulin Detemir in Patients With Type 2 Diabetes

Summary

The purpose of this study is to compare the effects of exenatide once weekly (QW) and insulin detemir with respect to glycemic control, body weight, lipids, safety, tolerability, and patient reported outcomes.

Timeline

Start

2009-10

Primary completion

2011-07

Completion

2011-12

Outcome

Met primary endpoint

registry analysis (superiority or other test); Exenatide Once Weekly vs Insulin Detemir; p <.0001; Odds Ratio (OR) 6.60 (95% CI 3.17 to 13.73); Regression, Logistic NCT01003184 ↗

release “In the study, 44.1 percent of patients receiving BYDUREON, compared with 11.4 percent of those treated with insulin detemir, met the primary composite endpoint” alkermes.com ↗

Publications

• Guja C, Frias JP, Suchower L, Hardy E, Marr G, Sjostrom CD, Jabbour SA. Safety and Efficacy of Exenatide Once Weekly in Participants with Type 2 Diabetes and Stage 2/3 Chronic Kidney Disease. Diabetes Ther. 2020 Jul;11(7):1467-1480. doi: 10.1007/s13300-020-00815-z. Epub 2020 Apr 18.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Exenatide	Peptide	2 mg	Subcutaneous
Comparator	insulin detemir	Protein / enzyme biologic	—	Subcutaneous

Indications